Loading…
Puma Biotechnology, Inc. is projected to rise to $10.61 by 2027, a +36% move from its current price of $7.83. PBYI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $7.67 | $7.84 | $8.00 | +0.08% |
| Jul 13 | $7.61 | $7.84 | $8.08 | +0.16% |
| Jul 14 | $7.57 | $7.85 | $8.14 | +0.24% |
| Jul 15 | $7.53 | $7.85 | $8.19 | +0.32% |
| Jul 16 | $7.50 | $7.86 | $8.24 | +0.40% |
| Jul 17 | $7.47 | $7.87 | $8.29 | +0.48% |
| Jul 18 | $7.45 | $7.87 | $8.33 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.45 | $7.87 | $8.33 | +0.56% |
| Week 2 | $7.32 | $7.92 | $8.57 | +1.12% |
| Week 3 | $7.23 | $7.96 | $8.77 | +1.68% |
| Week 4 | $7.16 | $8.01 | $8.95 | +2.24% |
| Week 5 | $7.10 | $8.05 | $9.12 | +2.81% |
| Week 6 | $7.06 | $8.10 | $9.28 | +3.39% |
| Week 7 | $7.02 | $8.14 | $9.44 | +3.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on developing and commercializing products to enhance cancer care in the United States and internationally.
It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks.
Puma Biotechnology was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology, Inc. (PBYI) currently trades at $8.26 per share and has a market cap of $420.43M.
The company is ranked 3113.
The near-term forecast features a 2026 average price of $8.26, with a min of $5.70 and a max of $12.21, and a neutral sentiment.
From 2027 onward, the forecast turns bullish with rising averages and improving ROI, reaching a 2030 avg of $23.40 and ROI 183.3, a 2040 avg of $78.40 ROI 849.1, and a 2050 avg of $206.71 ROI 2402.5.
A major floor 24.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.0% below — buyers have tended to step in here.
The nearest ceiling, 5.5% above — a clean break opens room to run.
A major ceiling 16.7% above — clearing it would confirm fresh momentum.
Key PBYI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PBYI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.04 | Sell | $8.02 | Sell |
| MA 10 | $8.09 | Sell | $7.99 | Sell |
| MA 20 | $7.79 | Buy | $7.82 | Buy |
| MA 50 | $7.41 | Buy | $7.49 | Buy |
| MA 100 | $7.09 | Buy | $7.11 | Buy |
| MA 200 | $6.36 | Buy | $6.41 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.50 | Neutral |
| Stoch RSI (14) | 12.74 | Buy |
| CCI (20) | 41.47 | Neutral |
| Williams %R (14) | -43.33 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -0.50 | Sell |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 56.67 | Neutral |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | 0.55 | Buy |
| Ultimate (7,14,28) | 51.00 | Neutral |
| Momentum (10) | 0.33 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 7.97 | Sell |
| ADX (14) | 18.57 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating upward momentum.
The moving averages sit at SMA50 $7.35 and SMA200 $6.28, with a near-term support of $6.81 and resistance of $8.26. The 30-day price range spans from $7.15 to $9.54, and annualized volatility runs around 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.70 | $7.83 | $11.49 | 0% | Neutral | |
| $8.63 | $10.61 | $13.70 | +36% | Bullish | |
| $10.85 | $13.63 | $18.12 | +74% | Bullish | |
| $14.13 | $18.07 | $24.59 | +131% | Bullish | |
| $17.03 | $22.11 | $30.68 | +182% | Bullish | |
| $20.26 | $26.67 | $37.65 | +241% | Bullish | |
| $21.84 | $29.11 | $41.74 | +272% | Bullish | |
| $23.86 | $32.19 | $46.81 | +311% | Bullish | |
| $27.52 | $37.55 | $55.33 | +380% | Bullish | |
| $30.85 | $42.54 | $63.45 | +443% | Bullish | |
| $50.84 | $73.60 | $115.52 | +840% | Bullish | |
| $124.08 | $194.79 | $329.69 | +23.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.70 | $7.83 | $9.42 | +0.00% |
| August 2026 | $7.06 | $8.29 | $9.95 | +5.82% |
| September 2026 | $7.14 | $8.42 | $10.19 | +1.59% |
| October 2026 | $7.18 | $8.51 | $10.39 | +1.16% |
| November 2026 | $7.50 | $8.93 | $10.95 | +4.83% |
| December 2026 | $7.80 | $9.31 | $11.49 | +4.31% |
Click any year to see its month-by-month PBYI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PBYI is projected to trade between $5.70 and $11.49, averaging $7.83 — a potential gain of 0% from today's $7.83. A consolidation phase looks the most probable path here.
Puma Biotechnology, Inc.'s 2027 outlook centres on $10.61, within a $8.63 to $13.70 range. That is up +36% on the projected 2026 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2028, PBYI could reach as high as $18.12, with a base case around $13.63 and support toward $10.85 — roughly +74% from $7.83. Buyers look set to stay in control over this stretch.
Expect PBYI to range from $14.13 to $24.59 through 2029. The $18.07 average target implies a +131% move from current prices. That is up +33% on the projected 2028 average. Momentum favours further upside here.
The PBYI price prediction for 2030 points to an average of $22.11 (low $17.03, high $30.68) — a potential gain of +182% on today's $7.83. Buyers look set to stay in control over this stretch.
In 2031, PBYI is projected to trade between $20.26 and $37.65, averaging $26.67 — a potential gain of +241% from today's $7.83. That is up +21% on the projected 2030 average. Momentum favours further upside here.
Puma Biotechnology, Inc.'s 2032 outlook centres on $29.11, within a $21.84 to $41.74 range. That is up +9% on the projected 2031 average. That marks a +272% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PBYI could reach as high as $46.81, with a base case around $32.19 and support toward $23.86 — roughly +311% from $7.83. Momentum favours further upside here.
Expect PBYI to range from $27.52 to $55.33 through 2034. The $37.55 average target implies a +380% move from current prices. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PBYI price prediction for 2035 points to an average of $42.54 (low $30.85, high $63.45) — a potential gain of +443% on today's $7.83. Momentum favours further upside here.
In 2040, PBYI is projected to trade between $50.84 and $115.52, averaging $73.60 — a potential gain of +840% from today's $7.83. That is up +73% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Puma Biotechnology, Inc.'s 2050 outlook centres on $194.79, within a $124.08 to $329.69 range. That is up +165% on the projected 2040 average. That marks a +23.9x change versus current levels. Momentum favours further upside here.
Investing $1,000 in PBYI today (≈ 127.713921 PBYI) could be worth
$24,877.43
+$23,877.43 (+2388%) by 2050 · US Dollar
Based on the average projected PBYI price of $194.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PBYIwould be worth at today's price.
$1,000 invested in PBYI on Jul 10, 2025 (≈ 284.090911 PBYI) would be worth
$2,224.43
+$1,224.43 (+122.4%) today · 2.22× · US Dollar
Based on a PBYI entry price of $3.52 vs. today's $7.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.26 | $947.94 | -5.2% |
| 1 month ago | $7.02 | $1,115.38 | +11.5% |
| 3 months ago | $7.78 | $1,006.43 | +0.6% |
| 6 months ago | $6.28 | $1,246.82 | +24.7% |
| 1 year ago | $3.52 | $2,224.43 | +122.4% |
| All time (5.0y) ago | $8.55 | $915.79 | -8.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PBYI forecast.
Our base-case forecast reaches $16.00 around 2029.
Implied market cap at $16.00: $814.39M
The multi-year forecast shows continued upside with bullish sentiment across the years. From 2027 onward, sentiment remains bullish as averages rise from $11.19 in 2027 to higher levels toward 2050, with meaningful increases by key milestone years.
Key milestones include 2030 with an average price of $23.40 and ROI of 183.3, 2040 with an average price of $78.40 and ROI of 849.1, and 2050 with an average price of $206.71 and ROI of 2402.5. The forecast signals strong long-run upside, but these are estimates and not guarantees; market conditions can change and outcomes may differ from the projections.
Tap a question to reveal the answer.
2030 avg $23.40; min $17.94; max $32.66; ROI 183.3; sentiment bullish.
Forecast shows bullish sentiment from 2027 onward with rising averages and ROI reaching 183.3% by 2030 and 2402.5% by 2050; 2026 avg $8.26 with neutral sentiment.
2033 max $49.75; 2034 max $59.60, with 2034 avg $40.16. The near-term max is below $50 in 2033, but later years show potential to exceed $50 according to the forecast.
Low $7.15; High $9.54.
Current price $8.26; Market cap $420.43M.
Puma Biotechnology, Inc. Community Discussion
0Share your Puma Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.